Joseph Truitt
CIK 1452429 · Chief Executive Officer · last filed 2026-09-10
Joseph Truitt is a Chief Executive Officer who has filed 29 SEC Form 4 insider transactions across 5 companies since 2009. The most recent filing, for IPSC, was dated Sep 10, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACHN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 GEORGE STREET
NEW HAVEN, CT 06511
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IPSC | Director | — | $1.78 | — | $0 | 1 | 2026-09-10 |
| LRMR | Director | 2,750 | $2.46 | $6.8K | $10.3K | 8 | 2026-05-20 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Chief Executive Officer | — | — | — | $0 | 3 | 2020-12-02 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Chief Executive Officer | 0 | — | — | -$1.11M | 16 | 2020-01-29 |
| ACHILLION PHARMACEUTICALS INC (TPTX) Delisted | VP, Chief Commercial Officer | — | $76.01 | — | $0 | 1 | 2009-01-07 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-10 | IPSC | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2025-05-14 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2023-05-18 | LRMR | Buy (P) | +2,750 | $10.3K | EDGAR |
| 2023-05-11 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2022-05-12 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2021-05-20 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2020-12-02 | BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Disp (D) | — | $0 | EDGAR |
| 2020-10-19 | BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.